Colesevelam: a new bile acid sequestrant

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary heart disease (CHD) is a leading cause of death in the US.
• Hyperlipidemia, characterized by high total and low-density lipoprotein (LDL) cholesterol, is a major risk factor for CHD.
• Effective lipid-lowering therapies are crucial for CHD prevention and management.

Purpose of the Study:

• To evaluate the efficacy and safety of colesevelam, a novel bile acid sequestrant, in managing hyperlipidemia.
• To assess colesevelam's impact on total cholesterol and LDL cholesterol levels.
• To compare the effects of colesevelam, alone and in combination with statins, on lipid profiles.

Main Methods:

• Review of short-term, placebo-controlled studies investigating colesevelam's effects on lipid levels.
• Analysis of data from combination therapy studies involving colesevelam with atorvastatin, lovastatin, or simvastatin.
• Assessment of colesevelam's formulation and potential for gastrointestinal tolerability.

Main Results:

• Colesevelam demonstrated significant reductions in total cholesterol (6-10%) and LDL cholesterol (9-20%) in short-term studies.
• Combination therapy with colesevelam and statins resulted in greater LDL cholesterol reduction than colesevelam monotherapy.
• The unique hydrogel formulation of colesevelam may mitigate common gastrointestinal adverse effects associated with bile acid sequestrants.

Conclusions:

• Colesevelam is an effective agent for lowering total and LDL cholesterol levels.
• Combination therapy with statins enhances the lipid-lowering effects of colesevelam.
• Colesevelam presents a favorable tolerability profile, potentially offering an advantage over existing bile acid sequestrants.